Eton Pharmaceuticals (NASDAQ: ETON) is a specialty pharmaceutical company that acquires, develops, and commercializes treatments for rare and ultra-rare diseases. Revenue comes primarily from direct product sales of FDA-approved drugs, with additional income from licensing arrangements that can include milestone payments and sales-based royalties. The company sells its commercial products through an internal sales force and outsources manufacturing to third-party contract manufacturers. Marketed products as of the FY2025 10-K (filed 2026-03-19) include INCRELEX, ALKINDI SPRINKLE, KHINDIVI, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous for Oral Solution, and Nitisinone, all targeting small patient populations with limited treatment alternatives. Pipeline candidate ET-600 had its NDA accepted by the FDA with a PDUFA date of February 25, 2026, with launch inventory scheduled for Q1 2026. The company carries debt through a credit agreement with SWK Funding LLC, amended most recently in September 2024.

Revenue model

Product sales of FDA-approved rare-disease drugs sold through an internal sales force; licensing revenue from partners including development milestone payments recognized upon achievement and sales-based royalties recognized when underlying sales occur.

Products and services

INCRELEX, ALKINDI SPRINKLE, KHINDIVI, GALZIN, PKU GOLIKE (branded products); Carglumic Acid (generic of Carbaglu, launched December 2021); Betaine Anhydrous for Oral Solution (generic of Cystadane, launched May 2023); Nitisinone (generic of Orfadin, launched February 2024); ET-600 (NDA under FDA review, PDUFA date February 25, 2026).

Customers and end markets

Patients with rare and ultra-rare inherited metabolic and endocrine conditions in the United States. End markets include NAGS deficiency, homocystinuria (estimated fewer than 2,000 U.S. patients), tyrosinemia type 1 (estimated fewer than 500 U.S. patients), and related rare pediatric disorders. Eton products are prescribed to very few Medicare patients, per FY2025 10-K disclosure.

Value-chain role

Specialty pharmaceutical acquirer and commercializer. Eton licenses or acquires marketing rights to approved or near-approved drugs, relies entirely on third-party contract manufacturers for API and finished drug product, and deploys an internal sales force for promotion.

Geographic exposure

United States primary commercial market, based on product approvals and sales force described in FY2025 10-K filing.

Source: SEC 10-K, filed 2026-03-19

Industry: Pharmaceutical Preparations Peers: 9 METERS BIOPHARMA, INC. NRX Pharmaceuticals Inc Enliven Therapeutics Inc Johnson & Johnson Journey Medical Corp OPIANT PHARMACEUTICALS, INC. Mystic Holdings Inc./NV Odonate Therapeutics, Inc.